Seroprevalence of Pertussis Among Children and Adolescents in Croatia

University Hospital for Infectious Diseases, Croatia1,500 enrolled

Overview

Pertussis is a vaccine preventable disease caused by Bordetella pertussis. Older children and adolescents with pertussis continue to be a significant source of infection for incompletely vaccinated infants who are in harm for developing severe disease. The primary objective of our study is to estimate the duration of protection elicited by the current vaccination schedule against pertussis in Croatia.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

1,500

Conditions

Immunogenicity, Vaccine

Interventions

ELISA IgG TestkitDIAGNOSTIC_TEST

All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * children and adolescents from 6 to 18 years of age treated through Emergency room and/or Day hospital of Pediatric Infectious Diseases Department at UHID; * appropriate vaccination with pertussis component containing vaccine by date and at the appropriate time, according to Croatian NIP proven by insight in the Vaccination Record Card * written informed consent obtained from the subject's parent or caregiver, as well as from participants ≥ 16 years old. Exclusion Criteria: * children under 6 years * children and adolescents with acute respiratory symptoms * children and adolescents with pertussis-like illness within 12 months * children and adolescents with unknown, uncompleted or irregular vaccination record * inpatients * children and adolescents with immunodeficiencies

Locations (1)

University Hospital for Infectious Diseases "Dr Fran Mihaljević"

Zagreb, Croatia

RECRUITING

Outcomes

Primary Outcomes

Waning of vaccine-induced immunity

Number of Participants In Each Specific Age Group With Negative Pertussis Toxin IgG Antibody Titre Measured by ELISA IgG Testkit

Time frame: 1 day

Secondary Outcomes

Seroprevalence

Prevalence of Pertussis Toxin IgG Antibody Titre At Each Specific Age Subgroup

Time frame: up to 6 months

Central Contacts

Goran Tešović

CONTACT

+385914012605 gtesovic@bfm.hr

Vedran Stevanović

CONTACT

+385914012787 vstevanovic@bfm.hr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.